
Imugene reports second complete response in Phase 1b trial for aggressive lymphoma treatment
Imugene Ltd announced a second complete response in its Phase 1b azer-cel trial targeting patients with mantle cell lymphoma (MCL) who had failed prior BTKi therapy. The patient showed complete tumor shrinkage by Day 28, earlier than expected, highli...

